Scope Fluidics Focuses on Bacteromic Sale Amid R&D Costs, Strong Cash Position

Warsaw – Scope Fluidics, the Warsaw Stock Exchange-listed developer of advanced diagnostic systems, is intensifying efforts to monetize its Bacteromic platform in 2026 while navigating research-driven losses, according to the company’s latest financial and strategic updates.

The firm, which four years ago sold its first major project for $130 million, is now seeking a buyer for Bacteromic—a system designed to rapidly assess antibiotic resistance in hospital-acquired bacterial infections. While the technology remains in the pre-revenue phase, Scope Fluidics reported a consolidated net loss of PLN 46.3 million (€10.3 million) in 2025 on minimal revenue of PLN 0.1 million, primarily due to ongoing R&D expenditures across its portfolio.

Despite the losses, the company maintains a robust liquidity position, ending 2025 with PLN 156.9 million (€35 million) in cash and equivalents. This financial cushion stems partly from the 2021 asset sale and a PLN 64 million gross capital raise via a share issuance last year.

“2025 marked a period of significant financial strengthening for the group,” said Szymon Ruta, Scope Fluidics’ CFO, in a regulatory filing. “The equity raise enhanced our flexibility, ensuring stable funding for operations and the advancement of key projects.”

Regulatory Progress and Commercial Strategy

Scope Fluidics secured CE certification for Bacteromic’s first-generation tests in early 2026, enabling European market entry. The company has since refined its commercialization roadmap, prioritizing two “Fast” diagnostic panels—rapid-testing solutions tailored for clinical urgency.

• The first Fast panel is expected to obtain U.S. FDA clearance by mid-2027, following its European debut in mid-2026.
• The second panel, however, faces delays. European certification, initially targeted for mid-2027, may now extend to late 2027 due to challenges in sourcing sufficient clinical samples. U.S. approval timelines remain undisclosed.

“Bacteromic is among the most comprehensive diagnostic solutions for antibiotic resistance today,” said Prof. Piotr Garstecki, Scope Fluidics’ CEO and a major shareholder. “Our 2026 priorities include advancing M&A discussions for this asset, initiating commercial sales, and expanding our project pipeline.”

Market Context and Outlook

Antibiotic resistance diagnostics represent a growing €1.5 billion+ global market, driven by rising hospital-acquired infections and regulatory pressures to curb antimicrobial overuse. Scope Fluidics’ technology aims to reduce testing times from days to hours, addressing a critical gap in infection management.

Analysts note that while the company’s burn rate remains elevated—reflecting its R&D-intensive model—the PLN 157 million war chest provides a multi-year runway. The success of Bacteromic’s sale or partnership will be pivotal in determining Scope Fluidics’ next phase, particularly as it balances innovation with shareholder returns.

The firm’s shares, traded on the Warsaw Stock Exchange’s main market, have reflected volatility amid the biotech sector’s broader challenges. However, the company’s disciplined capital allocation and regulatory milestones may offer stability as it transitions toward commercialization.

For further details, refer to Scope Fluidics’ regulatory filings or the Warsaw Stock Exchange disclosures.